Micellar Curcumin and Metabolic Syndrome Biomarkers

University of Hohenheim

Status and phase: Completed; Phase 2

Conditions: Metabolic Syndrome, Protection Against

Treatments: Dietary Supplement: Micellar curcumin; Dietary Supplement: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT01925547

0315679-HS3

Details and patient eligibility

About

The purpose of this study is to investigate the effect of micellar curcumin on inflammation and lipid metabolism markers in subjects at risk for the metabolic syndrome.

Enrollment: 42 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Total cholesterol > 5.2 mmol/L
• LDL cholesterol > 3.4 mmol/L
• Triglyceride > 2.26 mmol/L
• CRP > 2 mg/L

Exclusion criteria

• Intake of drugs or dietary supplements
• Pregnant women and breastfeeding mothers
• Smokers
• Previous illnesses such as heart attack, cancer or dementia
• Addiction

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

42 participants in 2 patient groups, including a placebo group

Micellar curcumin

Experimental group

Description:

Subjects receive three times per day four capsules of curcumin micelles. One capsule contains 20 mg of curcumin. At the beginning, after three and six weeks of intake, blood samples are collected.

Treatment:

Dietary Supplement: Micellar curcumin

Placebo

Placebo Comparator group

Description:

Subjects receive three times per day four capsules of placebo preparation. At the beginning, after three and six weeks of intake, blood samples are collected.

Treatment:

Dietary Supplement: Placebo